Clinical Trials Logo
  1. Home
  2. Acromegaly
  3. NCT00143416
  4. Details
NCT00143416 Clinical Trial

Long Term Study With B2036-PEG

Acromegaly Clinical Trial

Official title:
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00143416
Other study ID # A6291011
Secondary ID
Status Completed
Phase Phase 3
First received September 1, 2005
Last updated July 24, 2008
Start date April 2004
Est. completion date July 2007

Study information
Verified date July 2008
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Recruitment information / eligibility
Status Completed
Enrollment 16
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion Criteria:

- Switching to other therapeutic methods for acromegaly

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Pegvisomant

Locations
Country Name City State
Japan Pfizer Investigational Site Bonkyo-ku Tokyo
Japan Pfizer Investigational Site Gakuhara, Kishiwada, Osaka
Japan Pfizer Investigational Site Hamamatsu-shi Shizuoka-ken
Japan Pfizer Investigational Site Kobe City Hyogo Pref
Japan Pfizer Investigational Site Kozukue-cho, Kouhoku-ku, Yokohama-shi Kanagawa
Japan Pfizer Investigational Site Kyoto
Japan Pfizer Investigational Site Sannomaru-cho, Naka-ku, Nagoya-shi
Japan Pfizer Investigational Site Shinjuku-ku Tokyo

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
Secondary PK/PD evaluation
See also
  Status Clinical Trial Phase
Recruiting NCT06344650 - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting NCT02092129 - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. N/A
Completed NCT02012127 - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting NCT01265121 - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. N/A
Terminated NCT00765323 - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Phase 3
Completed NCT00500227 - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed NCT00531908 - Physiopathology of Sodium Retention in Acromegaly N/A
Completed NCT01278342 - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Phase 4
Active, not recruiting NCT01809808 - A Prospective Study of Outcome After Therapy for Acromegaly
Completed NCT00145405 - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Phase 4
Completed NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Phase 3
Recruiting NCT05401084 - Diet in the Management of Acromegaly N/A
Recruiting NCT00005100 - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly N/A
Completed NCT00521300 - Preoperative Octreotide Treatment of Acromegaly Phase 4
Completed NCT03548415 - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Phase 2
Not yet recruiting NCT04066569 - Reproducibility and Utility of OGTT in Acromegaly N/A
Not yet recruiting NCT05298891 - Hypoproteic Diet in Acromegaly N/A
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Active, not recruiting NCT03252353 - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Phase 3

External Links